報價延遲最少15分鐘:2024/05/21 18:14 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.51 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.07/-3.08
|
|
企業價值
478.33M
|
| 資產負債 |
|
每股賬面淨值
3.58
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
78.12M
|
|
每股收益
0.30
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/21 18:14 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. |